ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children’s Oncology Group AAML0531 Trial

Gemtuzumab-ozogamicin (GO), a humanized-anti-CD33 antibody linked with the toxin-calicheamicin-γ is a reemerging and promising drug for AML. Calicheamicin a key element of GO, induces DNA-damage and cell-death once the linked CD33-antibody facilitates its uptake. Calicheamicin efflux by the drug-tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Rafiee, Roya, Chauhan, Lata, Alonzo, Todd A., Wang, Yi-Cheng, Elmasry, Ahlam, Loken, Michael R., Pollard, Jessica, Aplenc, Richard, Raimondi, Susana, Hirsch, Betsy A., Bernstein, Irwin D., Gamis, Alan S., Meshinchi, Soheil, Lamba, Jatinder K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529443/
https://www.ncbi.nlm.nih.gov/pubmed/31113932
http://dx.doi.org/10.1038/s41408-019-0211-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529443/
https://www.ncbi.nlm.nih.gov/pubmed/31113932
http://dx.doi.org/10.1038/s41408-019-0211-y

Ejemplares similares